{"name":"Asahi Kasei Pharma America Corporation","slug":"asahi-kasei-pharma-america-corporation","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ART-123","genericName":"ART-123","slug":"art-123","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"ART-123","genericName":"ART-123","slug":"art-123","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOUEVmMzdtZEpkdzN0TzNDZFVnVVdESkNEUDNiN2tDdV9JeVQxejR4WWZLUVNOblQwMU43cnVMT0FPVEMzTkhnQXJ1VGhaclZ0QnptX2E5azdjNkdEMFRMMHNPWTRtb3g2ZEVYaFdFakFKSldPVURnaG5kT0Q3QTlZeFprV2xiLVZZRlFVakQ2NHhpQmFrZE9fTGZqbjhHRVJPQjRydGtGdzhodXU3MXRaWmdLQzY5bzNFbXUtUw?oc=5","date":"2026-02-26","type":"pipeline","source":"PharmTech.com","summary":"Impacts of Asahi Kasei’s Acquisition of Aicuris on Specialty Pharmaceutical Manufacturing - PharmTech.com","headline":"Impacts of Asahi Kasei’s Acquisition of Aicuris on Specialty Pharmaceutical Manufacturing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxPYlhJZVp2bThSWnhHVllDYmtQd2FqQ1JrYmZpdVBYamxFcXdpeFhXeG5TTXBxRC1xN1FNVDk1dVUwemdZQnRJREdHS0picnhpQ1YzN25uXzFpbGVWZVp4OTg2ZG9SWnplUTRHWTMyVm9KVEZZTTJCZ1kyOEQzRG1wUjFlYzk2UXZ2ekRRb2I0TGJWX3ZRalBmdWhQcEQ3SFZRR2g3OUJOT2ZELXczS2dGVXRPU0FSWkRUQmtGTkdhQTdBZ3NIYlViYUpqTG5zRVR6R2dJYWd5TjRMcHM?oc=5","date":"2026-02-26","type":"pipeline","source":"businesswire.com","summary":"Asahi Kasei Strengthens Global Pharmaceutical Platform with the Acquisition of Aicuris - businesswire.com","headline":"Asahi Kasei Strengthens Global Pharmaceutical Platform with the Acquisition of Aicuris","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxNWTlXcTlURFpLNV85V2gzcTZ1NzlPaGV0dXV3OVMtTEZpUFlRTFhVWTJ5ZHJhZUpkYzI5dWhGeG1MWWJxMTlxTlR2UWNJVllMMF9JY2RrNjVVb1dTdkRCSHVzeWtqNUJ1WlpXajRJZlFvT0haM0R5WGJhbExUQzV0Y2UwVGJwa3VHdC1zNWRiSnNDX052bURWR1BUcm1BSVFRTlk5TjR2UG5lbzduemFsYm1GZFUzTV9WX0xRbHU2SmtqZ2tVTThIVmFyTkNqODZlMDg5WUVhZjdLVDRaVzhIUE9yb0VfbHpxVnl6SlhFWC0xcmlha25pcDRQQTRXU3VzaVh1bm05aVdoT1E3cjJDdnF3bFhFRV81V3pJcTFUZEw?oc=5","date":"2026-02-25","type":"deal","source":"businesswire.com","summary":"Asahi Kasei Pharma Strengthens Preclinical Pipeline Through Exclusive Global License Agreement with Alchemedicine for Novel Lead Compounds - businesswire.com","headline":"Asahi Kasei Pharma Strengthens Preclinical Pipeline Through Exclusive Global License Agreement with Alchemedicine for No","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPMnlHUnlUTzhjMURJRkFReFFoWlVqTlN1d2ZHMlRycXlqOUdvM2VJYVg2VTRsVWFOQmJYYVpYa0NzX2lZbFZMVTc0X1ZuYllHS3J0RjhTQVVnaU5Xa01va2tDa3ZpQmVvSXhVOGc5MlBweWVwb1IwbHV1ZUJZaDFaLWptV3ZhY3dCQ3ZFbzlKR1d4UmJVVTVINzA4YV96NnYzT1ExTkhwSG5KMWd6?oc=5","date":"2026-02-25","type":"deal","source":"Contract Pharma","summary":"Asahi Kasei Enters Global License Agreement with Alchemedicine - Contract Pharma","headline":"Asahi Kasei Enters Global License Agreement with Alchemedicine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxOM1RvOUd5R3Bub1oxdkd5MGxvUmloQTh5aEsxY0ZfUDNJOUtoOXZ2aXk2ZlJ6Mzc1cTJ6dXByLUhQdHBPOHliUm03ZzdFclZJSkpxMENwNzB6ZkZXbW5LQXRfSnZJc2R1dW1kZ2ZwN0psb2hRVnJ1MW9JVVFHRWdxNC1fTXlRNWtiQXl5SGR6MmM?oc=5","date":"2026-02-19","type":"pipeline","source":"Yahoo Finance","summary":"MAIA Pharmaceuticals Selected by Asahi Kasei Pharma to Advance Teribone™ for US Osteoporosis Patients - Yahoo Finance","headline":"MAIA Pharmaceuticals Selected by Asahi Kasei Pharma to Advance Teribone™ for US Osteoporosis Patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPSjR3bERoLXhQR2hYc2tRVzdJeGlaTjctNG9WMmZRamM4cmVRNDNUUDY5YUlOVHlEQmN2cnNyV2FTRGhmTWgwcnlaOVd0SVVFa2VKVEtteFM3bm5xUllYajB6d3Q5MnpzeGRkdk13UldPUGIxM0JscXM1UV9BN1hVRmlNVFBscklPbk1EeV9EQ1lpTWRWZWhZTXJfak9ncm1RcnRpUw?oc=5","date":"2026-02-17","type":"deal","source":"BioWorld News","summary":"Asahi Kasei Pharma acquires rights to Alchemedicine compounds - BioWorld News","headline":"Asahi Kasei Pharma acquires rights to Alchemedicine compounds","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBSZkNkQXBHQTlyNHZtRDZ2ZjJET3V4U0pCMTFLLVl2YWRwMzdHY2g2NmozYndDanNSYkJFNGtLZmhCck45OFVjRTZHb2lfOTdKLVAtR2lLd2h3R1V1cDFN?oc=5","date":"2025-12-22","type":"pipeline","source":"asahi-kasei.com","summary":"Asahi Kasei Pharma to Relocate Global R&D Hub to Shonan iPark - asahi-kasei.com","headline":"Asahi Kasei Pharma to Relocate Global R&D Hub to Shonan iPark - asahi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxQdHBFTHRKbGV2aWFWUmJyNEpMR3FQRVlkSzdQdFp1bk5ONE43QXpQd0xZRHdsTjI1czhVTHRhQzJ4VUNfenZKZFVfY1g1dTZQbEF3RTM3aVhWLTQxUy1oQmNMRFl5cUdTdzF3N0NjTENnaF9raWZBYUhoMDAwRmcwd1pfUF9EcDB1bmJIZUhLM0Z4cnNMVjMtSW9WX1N1cll2UkRGYm51ZU1Bd3BJelFYRmNmaFFja2U0aFZTdkdDNmhIYmVaWDg5Nl9iNzBuSDliN0xxd0ZPQzFtOTBrNjB2SVFSVmVhb3E4LVFfOUY2aldSRGtlQVJCOVJ4b3JWODQzb1VZUXM1cTY?oc=5","date":"2025-07-03","type":"trial","source":"BioSpace","summary":"Asahi Kasei Pharma Starts Phase III Study of Promising CIPN Prevention Therapy, ART-123 (Recomodulin™), to Enhance Treatment Options Worldwide - BioSpace","headline":"Asahi Kasei Pharma Starts Phase III Study of Promising CIPN Prevention Therapy, ART-123 (Recomodulin™), to Enhance Treat","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxPNXNGWW1xNzU3SWJ2YS1DbUtXVEF0enpJeXg4Q2lLQlo4Mi1CODhVVURjZDFFYmNvUUlmUUFXbmIwSjNXYWlxNk1TSDFkQ3B0MW5vUWVIWVpKZHRqd1B0Tk5MS2tXcE9vdkJtRWpFcmpIdk5uZk9GQ3VCYmoyemRsQXdBU0ZJZ18xblFmVm1WUEZzRk81V2NpLW01YXVZYWdYRGVCUWZYSzZRdWNlTVYwX3FkSmUwelVucXJoeW4yLUNpRkU0WkE?oc=5","date":"2024-12-12","type":"deal","source":"BioPharma APAC","summary":"Asahi Kasei Pharma Expands Global Reach with Exclusive Anti-CX3CR1 Antibody License - BioPharma APAC","headline":"Asahi Kasei Pharma Expands Global Reach with Exclusive Anti-CX3CR1 Antibody License","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQby12WExKemFyVWh2anpfRk1wOVVkeXJvSl9DT3RqaDNxMHRvUWZlSmxNQUo3UkljdGRGVUk5dDRlelI2NWxtU183cHVpdmhlLTBzTHZiQUZXTFFZMHBXczYwUXZRbnAzNGdEcGxvZWctSlF0RjZLWVpSQ1hmQ0wwbm04U1ZYQ1JIRUFGNXVLS2MtMFZMcDVfMWFpdl9FaDIxRklHZmkyMVQ2OFBWRTdmTERwcWVYeVJwNXgwelVlZw?oc=5","date":"2024-12-11","type":"deal","source":"Stock Titan","summary":"Asahi Kasei Pharma Lands Exclusive License for Breakthrough Immunology Antibody, Eyes $3B Sales Target - Stock Titan","headline":"Asahi Kasei Pharma Lands Exclusive License for Breakthrough Immunology Antibody, Eyes $3B Sales Target","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNRk9SQ3RBVjBIQmVTUDZxY0RLQUFyYVNDdmxWLU1BMEY5VXktcUExc09FVTZ2SnUzR043VHhwdDF6OEphM2xwdGlFbm10M1g5MzJmSlhJTkxLTW5NLXJiU0tCdGJVcFBEMURKZTJlcF9rY3JVQjBGS1JrRG4wMGNROGNNLVczbHNqdVNfOXd5RXBMQQ?oc=5","date":"2024-05-28","type":"deal","source":"Fierce Pharma","summary":"Japan's Asahi Kasei puts up $1.06B offer to buy out Tarpeyo maker Calliditas - Fierce Pharma","headline":"Japan's Asahi Kasei puts up $1.06B offer to buy out Tarpeyo maker Calliditas","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxOMnQ3bzg0YVJFeGVPRjVGOW15Vkgya1BJRU9iU0loWkNTOHVEbEdvQW0wVjZHSVpzMzlhc0p2OURSTXZ6U0tvbWNDaERFOGY1MTRxTXQ3WW5LTHhMRjlvdmwxNFFnemgtTW4wRWJxTU9kNzh4djJ4QjVlQnBKX21OOFQ4S1lJRGVBRUpMZmM0Wk53b2pyQlE2ckM1bzNNZ2tKdXpiTzA2ei1YendZY1RzZi1abzZ5TVY2UEp6VVAtYjJNWnc?oc=5","date":"2021-01-28","type":"deal","source":"Eli Lilly","summary":"Lilly and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate - Eli Lilly","headline":"Lilly and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}